reasons for the downmove:
US Food and Drug Administration (FDA)
had raised concerns over the Troponin device’s temperature range
close facility in Sweden and move it to Ireland, which
will reduce its cost base to US$1.5mln from US$9mln
accounts will include a US$50mln write-off.
cutting 40 jobs.
Trinity will engage with the FDA for the approval